Biohaven Ltd
BHVNHealthcare|Biotechnology|USA
$15.55
-1.24 (-7.39%)
Tangible Book
$0.73
Upcoming Data Readouts (8)
Dec 2026
Est. completion
P2P3Focal Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893n=390
Jul 2027
Est. completion
Aug 2027
Est. completion
P2P3Parkinson Disease
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268n=550
Sep 2027
Est. completion
Jan 2028
Est. completion
P3Graves Disease
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056n=300
Feb 2028
Est. completion
P1P2Solid Tumor
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807n=500
Jun 2028
Est. completion
P2P3Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447n=2,250
Mar 2029
Est. completion
Awaiting Results (7)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P2P3
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Jun 2026
NA
Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
NCT06419322Sep 2024
P3
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553Sep 2024
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
NCT06529146